Evolent Health, Inc. (NYSE:EVH) Shares Sold by Values First Advisors Inc.

Values First Advisors Inc. trimmed its holdings in shares of Evolent Health, Inc. (NYSE:EVH) by 18.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,240 shares of the technology company’s stock after selling 5,889 shares during the period. Values First Advisors Inc.’s holdings in Evolent Health were worth $295,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Creative Planning lifted its holdings in shares of Evolent Health by 12.2% during the 2nd quarter. Creative Planning now owns 18,091 shares of the technology company’s stock valued at $346,000 after acquiring an additional 1,973 shares in the last quarter. GAMMA Investing LLC raised its position in Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after purchasing an additional 1,556 shares during the period. Friedenthal Financial purchased a new position in Evolent Health in the third quarter valued at about $723,000. Moody Aldrich Partners LLC acquired a new position in shares of Evolent Health during the third quarter worth about $1,421,000. Finally, US Bancorp DE boosted its position in shares of Evolent Health by 180.3% in the third quarter. US Bancorp DE now owns 6,579 shares of the technology company’s stock worth $186,000 after buying an additional 4,232 shares during the period.

Evolent Health Stock Down 2.6 %

NYSE:EVH opened at $9.60 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -10.55 and a beta of 1.45. Evolent Health, Inc. has a one year low of $9.45 and a one year high of $35.00. The stock has a 50-day simple moving average of $10.91 and a 200 day simple moving average of $19.43.

Analysts Set New Price Targets

EVH has been the topic of several analyst reports. BTIG Research dropped their target price on Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, December 3rd. JMP Securities dropped their price objective on shares of Evolent Health from $27.00 to $18.00 and set a “market outperform” rating on the stock in a research note on Friday, January 10th. Canaccord Genuity Group decreased their target price on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. UBS Group dropped their price target on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, January 16th. Finally, Royal Bank of Canada decreased their price objective on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Evolent Health has a consensus rating of “Buy” and an average target price of $18.38.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.